Press Releases August 7, 2026 08:45 AM

AVITA Medical Announces Participation at Canaccord Genuity Growth Conference

AVITA Medical to Present at Canaccord Genuity 46th Annual Growth Conference

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
RCEL

AVITA Medical, a leader in therapeutic acute wound care, announced its participation at the Canaccord Genuity Growth Conference taking place August 11-13, 2026, where CEO Cary Vance will speak. The company highlights its RECELL technology, FDA-approved for burn and trauma wound treatment, and other wound care products with approvals in multiple international markets.

AVITA Medical Announces Participation at Canaccord Genuity Growth Conference
RCEL
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • AVITA Medical will present at a major growth conference to showcase its wound care technologies.
  • RECELL is FDA-approved and leverages patients’ own skin cells to improve wound healing and recovery time.
  • The company holds international certifications for its products, expanding its global market reach.

VALENCIA, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced it will be participating at the Canaccord Genuity 46th Annual Growth Conference in Boston, taking place August 11–13, 2026. 

AVITA Medical President and CEO Cary Vance will be speaking on Wednesday, August 12, 2026, at 8:00 a.m. Eastern Time. A live webcast and replay will be available under the Investor Relations Events & Presentations section of AVITA Medical’s website, at: https://ir.avitamedical.com/events-and-presentations

Investors attending the conference may request a one-on-one meeting with AVITA Medical through their Canaccord Genuity sales representative.

About AVITA Medical, Inc.

AVITA Medical® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is RECELL®, approved by the FDA for the treatment of thermal burn and trauma wounds. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin™, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the exclusive rights to market, sell, and distribute Cohealyx®, an AVITA Medical-branded collagen-based dermal matrix, and the exclusive rights to manufacture, market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix.

In international markets, RECELL is approved to promote skin healing in a wide range of applications, including thermal burn and trauma wounds. RECELL and RECELL GO® are CE-marked in Europe, have TGA certification in Australia, and are listed with Medsafe in New Zealand; RECELL is PMDA-approved in Japan.

To learn more, visit www.avitamedical.com.

Investor & Media Contact:
Ben Atkins
Phone +1-805 341 1571
investor@avitamedical.com | media@avitamedical.com

Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.

©2026 AVITA Medical. AVITA Medical®, the AVITA Medical logo, Cohealyx®, RECELL®, RECELL GO®, and Spray-On SkinTM Cells are trademarks of AVITA Medical. PermeaDerm® is a registered trademark owned by Stedical Scientific, Inc. All other trademarks are the properties of their respective owners.


Risks

  • Conference participation typically does not guarantee immediate commercial success or sales growth, leading to uncertain short-term stock impact.
  • The market for advanced wound care products is competitive, and regulatory approvals in various jurisdictions could pose challenges.
  • Dependence on successful commercialization of RECELL and related products exposes the company to product adoption and reimbursement risks.

More from Press Releases

Vicor acquires sites for additional ChiP fabs Sep 11, 2026 DoubleDown Interactive to Donate $10,000 to the ASPCA® Sep 11, 2026 SEALSQ Reports H1 2026 Financial and Operational Results; Revenue Increases 131% to $11.2 Million; FY2026 Guidance Reaffirmed Sep 11, 2026 Futuremain Co., Ltd. enters into definitive business combination agreement with ChampionsGate Acquisition Corp Sep 11, 2026 FingerMotion’s New Management Highlights Strengthened Liquidity and Reduced Cash Burn in its First 30 Days Sep 11, 2026